Abstract
e14101Background: PQR309 is an orally bioavailable, pan-PI3K, mTORC1 and mTORC2 inhibitor, in clinical development for the therapy of solid tumors and hematologic malignancies. The aim of this work...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.